Compare GEMI & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GEMI | MDXG |
|---|---|---|
| Founded | 2014 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 666.3M | 672.8M |
| IPO Year | 2025 | 2007 |
| Metric | GEMI | MDXG |
|---|---|---|
| Price | $4.13 | $4.83 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | $5.17 | ★ $7.40 |
| AVG Volume (30 Days) | ★ 2.3M | 1.1M |
| Earning Date | 11-09-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.86 | 14.29 |
| EPS | N/A | ★ N/A |
| Revenue | $179,572,000.00 | ★ $418,630,000.00 |
| Revenue This Year | $2.62 | N/A |
| Revenue Next Year | $22.07 | $21.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 26.31 | 19.99 |
| 52 Week Low | $3.39 | $3.03 |
| 52 Week High | $23.30 | $7.97 |
| Indicator | GEMI | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 37.76 | 64.55 |
| Support Level | $4.00 | $4.37 |
| Resistance Level | $5.02 | $4.99 |
| Average True Range (ATR) | 0.30 | 0.17 |
| MACD | -0.15 | -0.01 |
| Stochastic Oscillator | 2.84 | 74.58 |
Gemini Space Station Inc is engaged on unlocking the next era of financial, creative, and personal freedom. It envisions a future where crypto will redesign the global financial system, the internet, and money in a way that provides greater choice, independence, and opportunity for all. As a trusted bridge between the traditional financial system and the emerging crypto economy, It is providing access for individuals and institutions to a decentralized future that is more open, fair, and secure. Its core exchange product has expanded over time to become a comprehensive platform for its users to engage with the crypto economy, including a derivatives exchange, staking services, an over-the-counter (OTC) trading desk, institutional-grade custody, and others.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.